v3.10.0.1
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
Sep. 30, 2018
Dec. 31, 2017
Current assets:    
Cash and cash equivalents $ 20,097,000 $ 20,730,000 [1]
Accounts receivable, net of allowance for doubtful accounts of $304 and $221 as of September 30, 2018 and December 31, 2017, respectively 4,991,000 6,213,000 [1]
Inventory 4,497,000 2,390,000 [1]
Prepaid expenses and other current assets 2,680,000 2,741,000 [1]
Total current assets 32,265,000 32,074,000 [1]
Property and equipment, net 2,011,000 1,303,000 [1]
Investment in limited liability company 1,961,000 2,500,000 [1]
Other assets 201,000 202,000 [1]
Total assets 36,438,000 36,079,000 [1]
Equity    
Common stock, $0.0001 par value; 75,000,000 shares authorized as of September 30, 2018 and December 31, 2017; 31,523,454 and 19,503,558 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively 3,000 2,000 [1]
Additional paid-in capital 139,123,000 102,979,000 [1]
Accumulated deficit (141,893,000) (105,581,000) [1]
Total stockholders’deficit (2,767,000) (2,600,000) [1]
Total liabilities and stockholders’ deficit 36,438,000 36,079,000 [1]
Current liabilities:    
Accounts payable 3,562,000 4,799,000 [1]
Accrued liabilities 5,125,000 4,605,000 [1]
Total current liabilities 8,687,000 9,404,000 [1]
Note payable, noncurrent portion 30,124,000 28,948,000 [1]
Other noncurrent liabilities 394,000 327,000 [1]
Total liabilities 39,205,000 38,679,000 [1]
Commitments and contingences (Note 7)
[1] The condensed consolidated balance sheet as of December 31, 2017 has been derived from the audited consolidated financial statements as of that date.

Source

v3.10.0.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Revenue $ 4,821 $ 4,070 $ 14,045 $ 10,187
Cost of revenue 3,327 2,059 8,390 5,515
Gross profit 1,494 2,011 5,655 4,672
Operating expenses:        
Research and development 3,442 3,464 10,870 9,292
Selling, general and administrative 9,114 7,369 27,482 19,681
Total operating expenses 12,556 10,833 38,352 28,973
Loss from operations (11,062) (8,822) (32,697) (24,301)
Interest expense, net (1,106) (777) (3,239) (2,385)
Other expense, net (4) (16) (14) (49)
Net loss from consolidated companies (12,172) (9,615) (35,950) (26,735)
Loss from minority interest in limited liability company (132) (539)
Comprehensive and net loss $ (12,304) $ (9,615) $ (36,489) $ (26,735)
Net loss per share:        
Basic and diluted (in dollars per share) $ (0.39) $ (0.50) $ (1.23) $ (1.59)
Weighted average shares used in computing net loss per common share:        
Basic and diluted (in shares) 31,490,578 19,408,920 29,568,236 16,843,706

Source

v3.10.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Cash flows from operating activities:    
Net loss $ (36,489,000) $ (26,735,000)
Adjustments to reconcile net loss to net cash used in operating activities:    
Provision for doubtful accounts 103,000
Depreciation and amortization 545,000 318,000
Stock-based compensation 2,294,000 1,314,000
Fair value of common stock issued 256,000 260,000
Non-cash interest expense 1,176,000 762,000
Loss from minority interest in limited liability company 539,000
Changes in assets and liabilities:    
Accounts receivable 1,119,000 (2,742,000)
Inventory (2,317,000) 422,000
Prepaid expenses and other current assets 61,000 (2,151,000)
Other noncurrent assets 1,000 24,000
Accounts payable (1,297,000) 483,000
Accrued and other liabilities 502,000 1,747,000
Other noncurrent liabilities 262,000 24,000
Net cash used in operating activities (33,245,000) (26,274,000)
Cash flows from investing activities:    
Purchase of property and equipment (983,000) (810,000)
Investment in limited liability company (2,500,000)
Net cash used in investing activities (983,000) (3,310,000)
Cash flows from financing activities:    
Proceeds from sale of common stock, net of issuance costs 33,407,000 31,440,000
Proceeds from note payable 19,214,000
Repayments of note payable (10,000,000)
Proceeds from issuance of common shares from employee stock purchase plan 188,000
Proceeds from exercise of stock options 31,000
Proceeds from exercise of warrant 20,000
Net cash provided by financing activities 33,595,000 40,705,000
Net increase (decrease) in cash and cash equivalents (633,000) 11,121,000
Cash and cash equivalents - beginning of period 20,730,000 [1] 8,086,000
Cash and cash equivalents - end of period 20,097,000 19,207,000
Supplemental disclosure:    
Cash paid for interest 1,991,000 1,619,000
Cash paid for income taxes 2,000
Supplemental disclosure of cash flow information as of end of period:    
Issuance of warrants in connection with note payable 940,000
Issuance of note payable in settlement of accrued interest 934,000 285,000
Net transfer of equipment between inventory and property and equipment $ 210,000 $ 362,000
[1] The condensed consolidated balance sheet as of December 31, 2017 has been derived from the audited consolidated financial statements as of that date.

Source